Subcutaneous and orthotopic pancreatic tumour models, and PDOs in the combination‐treated group were markedly smaller than those in the control or gemcitabine‐alone groups, which demonstrated that targeting ARPC1B+ CSCs by CK‐636 can sensitise pancreatic cancer to gemcitabine. This evidence concerns the gene ARPC1B and pancreatic neoplasm.